Ferring

Paul Korner, M.D., M.B.A. has been named Senior vice president of the Ferring International PharmaScience Center U.S. (FIPCUS), the drug development subsidiary for Ferring Pharmaceuticals Inc. Dr. Korner was formerly vice president, Medical Affairs for Ferring’s Infertility, Orthopedics, Urology, and Gastroenterology therapeutic areas, as well as Product Safety. In his new role, Dr. Korner will be responsible for the clinical management of U.S. drug development.

“Dr. Korner has made tremendous strides in his first six months with Ferring, and is exceptionally well qualified to lead the clinical programs at our PharmaScience Center,” said Wayne Anderson, president and chief executive officer of Ferring Pharmaceuticals, and chairman of FIPCUS. “He will oversee the drug development of our rich pipeline of products as we continue our quest to achieve rapid new drug approvals by identifying, improving and commercializing late-stage or marketed products in our clinical specialty areas.”

Dr. Korner joined Ferring in 2008 with a broad range of experience in medical affairs, clinical development, management and business development. During his first six months at Ferring, he restructured the Medical Affairs and Product Safety departments, created a Medical Information department, and was instrumental in the pre-launch activities for newly approved degarelix for injection.

Prior to joining the company, Dr. Korner was vice president of Medical Affairs, Women’s Healthcare at Bayer HealthCare Pharmaceuticals, where his group supported the U.S. Women’s Healthcare business unit, and managed medical experts supporting Phase II and III development projects. He has also served as executive director of Medical Affairs, Female Healthcare at Berlex Laboratories and senior director of Clinical Research and Development, Women’s Health and Bone Repair for Wyeth Research.